Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index up +0.35% in March; Emerging Markets Index jumps +2.30%

Tuesday, April 19, 2011
Opalesque Industry Update - Hedge funds gained 0.35% in March according to the Barclay Hedge Fund Index compiled by BarclayHedge. Year-to-date, the Index is up 1.95%.

“The earthquake, tsunami and nuclear disaster in Japan, increasing turmoil in the Middle East, and the outlook for higher interest rates in the future helped to drive stock and bond prices lower in developed nations,” says Sol Waksman, founder and president of BarclayHedge.

“In spite of these headwinds, hedge funds were able to eke out a small gain for the month.”

Eleven of Barclay’s 18 hedge fund indices were in positive territory in March. The Barclay Emerging Markets Index led the way with a 2.30% gain. The Healthcare & Biotechnology Index was up 0.70%, Equity Market Neutral and Convertible Arbitrage both gained 0.60%, and Fixed Income Arbitrage rose 0.56%.

“All of the regional MSCI emerging markets indices were profitable last month,” says Waksman. “Asia led the sector with a gain of 7.06 percent for March.”

The Equity Short Bias Index lost 1.85% in March, and the Pacific Rim Equities Index was down 1.35%.

All but two of the hedge fund indices tracked by BarclayHedge are profitable at the end of the first quarter of 2011. The Technology Index is up 4.85%, Convertible Arbitrage has gained 4.20%, Distressed Securities added 3.73%, and the Fixed Income Arbitrage Index is up 3.67%.

Equity Short Bias and Global Macro are the only losing hedge fund strategies in 2011, down 5.63% and 0.43% respectively year-to-date.

The Barclay Fund of Funds Index slipped 0.07% in March, but is still up 0.94% after three months.

(press release)

Sol Waksman is an experienced media source, providing perspectives on hedge fund and managed futures trends. For more commentary or background, call 641-472-3456 or email swaksman@barclayhedge.com.

BarclayHedge was founded in 1985 and actively tracks more than 6,000 hedge funds, funds of hedge funds, and managed futures programs. Each month Barclay provides updated performance rankings for 38 Hedge Fund categories and 16 CTA categories. Institutional investors, brokerage firms and private banks worldwide utilize BarclayHedge indices as performance benchmarks for the hedge fund and managed futures industries...Full performance table:Source
KM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its